Zomedica Corp. [ZOM] moved up 17.01: Why It’s Important

Zomedica Corp. [AMEX: ZOM] jumped around 0.04 points on Tuesday, while shares priced at $0.29 at the close of the session, up 17.01%. The company report on January 17, 2023 that Sidoti’s January Micro-Cap Conference.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. The links can also be found at www.sidoticonference.com

Zomedica Corp. stock is now 79.39% up from its year-to-date (YTD) trading value. ZOM Stock saw the intraday high of $0.32 and lowest of $0.25 per share. The company’s 52-week high price is 0.50, which means current price is +84.36% above from all time high which was touched on 01/17/23.

Compared to the average trading volume of 8.21M shares, ZOM reached a trading volume of 45273648 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Zomedica Corp. [ZOM]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZOM shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZOM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Dawson James have made an estimate for Zomedica Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 06, 2023.

The Average True Range (ATR) for Zomedica Corp. is set at 0.02, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 16.95. The Price to Book ratio for the last quarter was 1.08, with the Price to Cash per share for the same quarter was set at 0.12.

How has ZOM stock performed recently?

Zomedica Corp. [ZOM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.01. With this latest performance, ZOM shares gained by 51.27% in over the last four-week period, additionally plugging by 14.62% over the last 6 months – not to mention a drop of -12.74% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 80.90, with the RSI for the last a single of trading hit 87.00, and the three-weeks RSI is set at 74.90 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.2052, while it was recorded at 0.2566 for the last single week of trading, and 0.2413 for the last 200 days.

Zomedica Corp. [ZOM]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Zomedica Corp. [ZOM] shares currently have an operating margin of -517.14 and a Gross Margin at +46.32. Zomedica Corp.’s Net Margin is presently recorded at -444.78.

Return on Equity for this stock declined to -11.01, with Return on Assets sitting at -10.61.

Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.50 and a Current Ratio set at 17.80.

Insider trade positions for Zomedica Corp. [ZOM]

There are presently around $27 million, or 9.70% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 46,329,005, which is approximately 5.111% of the company’s market cap and around 1.48% of the total institutional ownership; BLACKROCK INC., holding 11,320,780 shares of the stock with an approximate value of $3.31 million in ZOM stocks shares; and CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., currently with $3.27 million in ZOM stock with ownership of nearly 0.179% of the company’s market capitalization.

Positions in Zomedica Corp. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 25 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 3,348,588 shares. Additionally, 35 investors decreased positions by around 5,731,699 shares, while 42 investors held positions by with 83,114,606 shares. The mentioned changes placed institutional holdings at 92,194,893 shares, according to the latest SEC report filing. ZOM stock had 10 new institutional investments in for a total of 500,905 shares, while 16 institutional investors sold positions of 1,776,674 shares during the same period.


Please enter your comment!
Please enter your name here